Supplier News Breaks Archives
Perrigo begins full-scale rollout of generic Mucinex
March 19th, 2013
ALLEGAN, Mich. – Perrigo Co. has begun shipping guaifenesin 600-mg extended-release tablets, an expectorant, to retail and wholesale customers.
The company said Monday that its product marks the first generic equivalent to Reckitt Benckiser's Mucinex 600-mg extended release tablets.
According to Perrigo, the product will be packaged and marketed under store brands and proprietary brands.
Guaifenesin is indicated to relieve chest congestion and make coughs more productive. Mucinex 600-mg extended release tablets had sales of about $135 million through food, drug and mass merchandisers over the last 12 months, Perrigo reported.
"This launch is representative of the Perrigo team's abilities to overcome challenging circumstances as evidenced by this product's complex formulation and patent challenges," Perrigo chairman and chief executive officer Joseph Papa said in a statement. "The team worked diligently to formulate the product, prove the product's noninfringement to existing patents, validate and achieve commercial production, and bring the product to market. Perrigo's achievement represents the first store-brand equivalent to be approved by the U.S. Food and Drug Administration and marketed to consumers as a high-quality store brand product that will represent considerable savings when compared to the national brand."
Last April, Perrigo said it had begun rolling out guaifenesin 600-mg extended-release tablets packaged in bottles "to a number of customers."
In January 2012, Perrigo announced that it won a summary judgment in patent litigation for its planned generic version of Mucinex and planned to launch the product within 90 days. Perrigo was sued by Adams Respiratory Therapeutics Inc., a subsidiary of Reckitt Benckiser Group, the New Drug Application holder and patent owner for Mucinex.
The Food and Drug Administration approved Perrigo's Mucinex generic in late 2011.